GenPharm International

Case Analysis

Provides an overview of the founding and development of the biotechnology company, GenPharm International, Inc., with a particular focus on its globalization strategy. GenPharm was founded in 1989 and quickly became a pioneer in the field of transgenic animal technology. Between 1991 and 1994, the company is pursuing cutting-edge research in the field of transgenic animal technology established cooperation agreements with several leading companies, and raised millions of dollars. In February 1994 … Read more »

Provides an overview of the founding and development of the biotechnology company, GenPharm International, Inc., with a particular focus on its globalization strategy. GenPharm was founded in 1989 and quickly became a pioneer in the field of transgenic animal technology. Between 1991 and 1994, the company is pursuing cutting-edge research in the field of transgenic animal technology established cooperation agreements with several leading companies, and raised millions of dollars. In February 1994 GenPharm preparation for an initial public offering (IPO) was to make their shares if a competitor filed a lawsuit alleging that GenPharm had misappropriated its trade secrets. GenPharm Board decided not to proceed with the planned IPO, and the company was forced to reduce the size and change the nature of its activities in 1995 and 1996. In March 1997, the legal situation was resolved with a settlement and cross-license agreement. Shortly thereafter, the Board received an offer from a publicly traded biotechnology company Medarex, Inc. to GenPharm for purchase of up to $ 65,000,000. The case ends asking the students a recommendation to the board regarding GenPharm to develop the acquisition.
«Hide

from
George Foster,
Andrea Higuera
Source: Stanford Graduate School of Business
49 pages.
Release Date: 5th September 2002. Prod #: IB38-PDF-ENG
GenPharm International HBR case solution